bluuebunny/crossref_metadata_2025_split huggingface dataset:
An executive-functions-based reading training enhances sensory-motor systems integration during reading fluency in children with dyslexia
Authors: Farah Rola , Dworetsky Ally , Coalson Rebecca S , Petersen Steven E , Schlaggar Bradley L , Rosch Keri S , Horowitz-Kraus Tzipi 
Published: April 2024

Abstract
The Simple View of Reading model suggests that intact language processing and word decoding lead to proficient reading comprehension, with recent studies pointing at executive functions as an important component contributing to reading proficiency. Here, we aimed to determine the underlying mechanism(s) for these changes. Participants include 120 8- to 12-year-old children (n = 55 with dyslexia, n = 65 typical readers) trained on an executive functions–based reading program, including pre/postfunctional MRI and behavioral data collection. Across groups, improved word reading was related to stronger functional connections within executive functions and sensory networks. In children with dyslexia, faster and more accurate word reading was related to stronger functional connections within and between sensory networks. These results suggest greater synchronization of brain systems after the intervention, consistent with the “neural noise” hypothesis in children with dyslexia and support the consideration of including executive functions as part of the Simple View of Reading model.
Hyaluronic acid microresonators for memorable humidity sensing
Authors: Liao Hsin-Yen , Heah Wey Yih , Suharman  , Yamagishi Hiroshi , Yamamoto Yohei 
Published: April 2024

Abstract
Self-assembled hyaluronic acid (HA) microspheres are utilized for memorable optical humidity sensing. Because of the extremely high hygroscopic property of HA, the microsphere deforms in a highly humid atmosphere and the shape change is irreversible, thereby memorizing the history of the humidity change. The optically memorable humidity sensor can notify whether the humidity exceeds the upper limit of 50%.
Origin of Antimicrobial Therapy
Authors: Kazanjian Powel 
Published: April 2024

Abstract
Medical historians typically situate the origins of the antimicrobial era during the early germ period at the turn of the 20th century. They have regarded the development of chemical compounds designed to treat infectious diseases by killing their causative germ as the beginning of the antimicrobial era. Scholars, however, had been speculating about the causal relationship between germs and diseases for centuries beforehand. One of them also addressed the practical applications of this theory. The Italian physician Fracastoro proposed in 1546 that infectious diseases could be treated by administering substances to antagonize disease causing germs. He claimed that health could be restored to people who became ill with infections by nullifying the responsible germs at a time when investigators could not see germs or investigate their ability to cause disease. The long genealogy of antimicrobial therapy from its conception to its fruition took place over the span of several centuries.
The Impact of Pretransplant Respiratory Virus Detection on Posttransplant Outcomes in Children Undergoing Hematopoietic Cell Transplantation
Authors: Kim Sara Ruth , Nordlander Anna , Xie Hu , Kim Yae-Jean , Ogimi Chikara , Thakar Monica S , Leisenring Wendy , Englund Janet A , Boeckh Michael , Waghmare Alpana 
Published: April 2024

Abstract

Background
Pretransplant respiratory virus (RV) infections have been associated with negative transplant outcomes in adult hematopoietic cell transplantation (HCT) recipients. In the era of HCT delay because of high-risk RVs, we examined the impact of pretransplant RV detection on transplant outcomes in pediatric HCT recipients.

Methods
This retrospective cohort study included pediatric myeloablative allogeneic HCT recipients from 2010 to 2019. All patients were screened for RV at least once within 90 days before HCT using reverse transcriptase polymerase chain reaction (PCR), regardless of symptoms. Posttransplant outcomes included days alive and out of hospital and progression to lower respiratory tract infection (LRTI).

Results
Among 310 patients, 134 had an RV detected in the 90 days before HCT. In univariable analysis, transplant factors including younger age, total body irradiation, umbilical cord blood transplantation, lymphocyte count &lt;100/mm3, HCT comorbidity index score ≥3, and viral factors including symptomatic infection, human rhinovirus as a virus type, and symptomatic pretransplant upper respiratory tract infection were associated with fewer days alive and out of hospital. In multivariable analysis, transplant factors remained significant, but not viral factors. There was a higher incidence of progression to posttransplant LRTI with the same pretransplant RV if the last positive PCR before HCT was ≤30 days compared with &gt;30 days (P = .007).

Conclusions
In the setting of recommending HCT delay for high-risk RVs, symptomatic upper respiratory tract infection, including human rhinovirus infections, may lead to increased duration of hospitalization and early progression to LRTI when transplantation is performed within 30 days of the last positive PCR test.
Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis
Authors: Shivaraj Kiran , Tchakarov Amanda , Dong Yanlan , Lin Jamie S 
Published: April 2024

ABSTRACT
Immune checkpoint inhibitor (ICI)-associated immune nephritis or acute interstitial nephritis (AIN) is one of the rare but known complication of ICI therapy. Guidelines recommend treatment of ICI-associated AIN with steroids, then TNF-alpha inhibitor infliximab. However, some cases are refractory to these therapies, potentially due to insufficient cytokine blockade. This is the first case where a 65-year-old female with metastatic lung adenocarcinoma, requiring high maintenance doses of steroids for immune nephritis was treated with tofacitinib, an oral Janus kinase (JAK) inhibitor. Tofacitinib enabled successful steroid tapering and might be a therapy option for refractory immune nephritis.
Biomarkers in clinical epidemiology studies
Authors: Zoccali Carmine , Tripepi Giovanni , Stel Vianda , Fu Edouard L , Mallamaci Francesca , Dekker Friedo , Jager Kitty J 
Published: April 2024

ABSTRACT
This paper discusses the use of biomarkers in clinical practice and biomedical research. Biomarkers are measurable characteristics that can be used to indicate the presence or absence of a disease or to track the progression of a disease. They can also be used to predict how a patient will respond to a particular treatment. Biomarkers have enriched clinical practice and disease prognosis by providing measurable characteristics that indicate biological processes. They offer valuable insights into disease susceptibility, progression, and treatment response, aiding drug development and personalized medicine. However, developing and implementing biomarkers come with challenges that must be addressed. Rigorous testing, standardization of assays, and consideration of ethical factors are crucial in ensuring the reliability and validity of biomarkers.
Reliability is vital in biomarker research. It ensures accurate measurements by preventing biases and facilitating robust correlations with outcomes. Conversely, validation examines which and how many biomarkers correspond to theoretical constructs and external criteria, establishing their predictive value. Multiple biomarkers are sometimes necessary to represent the complex relationship between exposure and disease outcomes accurately.
Susceptibility factors are pivotal in disease states' complex interaction among genetic and environmental factors. Gaining a comprehensive understanding of these factors is essential for effectively interpreting biomarker data and maximizing their clinical usefulness. Using well-validated biomarkers can improve diagnoses, more effective treatment evaluations, and enhanced disease prediction. This, in turn, will contribute to better patient outcomes and drive progress in medicine.
Economics of Emergency Department Visits by Patients With Inflammatory Bowel Disease: A Real-World Analysis
Authors: Clarke Kofi , Momin Arsh , Rosario Michelle , Stuart August , Dalessio Shannon , Tinsley Andrew , Williams Emmanuelle , Coates Matthew 
Published: April 2024

Abstract

Background
Inflammatory bowel disease (IBD) is associated with significant psychosocial, economic, and physical burden on patients. IBD care in the United States results in significant healthcare expenditure with recurring emergency department (ED) care and hospital admissions. Despite advances in therapy and improved access to specialty care, there is still room for improvement in cost-efficient care. Specialty medical homes and interdisciplinary care models have emerged as ways to improve medical care, patient outcomes, and quality of life, as well as improve the impact of healthcare costs. There is limited real-world data on cost in the United States, with many articles citing cost estimates from models.

Methods
We analyzed real-world data from our tertiary care center with a focus on recurrent ED visits by IBD patients. Descriptive statistics were used for a cost analysis of multiple ED visits by IBD patients. Patients with ≥4 visits to the ED in a 6-month period were described as SuperUsers and were included in a separate analysis. The cost of hospitalization was also included.

Results
Total cost associated with all ED visits from SuperUsers were $72 999.57 with an average of $6636.32 per patient. When the patients were admitted, the total cost of ED visits and hospitalizations was $721 461.52, with an average of $65 587.41 per patient.

Conclusions
ED utilization by IBD patients with or without hospitalization is expensive and is typically driven by a cohort of SuperUsers. More work needs to be done to improve cost-effectiveness in IBD care, including reducing the frequency of ED visits.
Serine protease inhibitor, SerpinA3n, regulates cardiac remodelling after myocardial infarction
Authors: Sun Qihao , Chen Wei , Wu Rimao , Tao Bo , Wang Ping , Sun Baiming , Alvarez Juan F , Ma Feiyang , Galindo David Ceja , Maroney Sean P , Saviola Anthony J , Hansen Kirk C , Li Shen , Deb Arjun 
Published: April 2024

Abstract

Aims
Following myocardial infarction (MI), the heart repairs itself via a fibrotic repair response. The degree of fibrosis is determined by the balance between deposition of extracellular matrix (ECM) by activated fibroblasts and breakdown of nascent scar tissue by proteases that are secreted predominantly by inflammatory cells. Excessive proteolytic activity and matrix turnover has been observed in human heart failure, and protease inhibitors in the injured heart regulate matrix breakdown. Serine protease inhibitors (Serpins) represent the largest and the most functionally diverse family of evolutionary conserved protease inhibitors, and levels of the specific Serpin, SerpinA3, have been strongly associated with clinical outcomes in human MI as well as non-ischaemic cardiomyopathies. Yet, the role of Serpins in regulating cardiac remodelling is poorly understood. The aim of this study was to understand the role of Serpins in regulating scar formation after MI.

Methods and results
Using a SerpinA3n conditional knockout mice model, we observed the robust expression of Serpins in the infarcted murine heart and demonstrate that genetic deletion of SerpinA3n (mouse homologue of SerpinA3) leads to increased activity of substrate proteases, poorly compacted matrix, and significantly worse post-infarct cardiac function. Single-cell transcriptomics complemented with histology in SerpinA3n-deficient animals demonstrated increased inflammation, adverse myocyte hypertrophy, and expression of pro-hypertrophic genes. Proteomic analysis of scar tissue demonstrated decreased cross-linking of ECM peptides consistent with increased proteolysis in SerpinA3n-deficient animals.

Conclusion
Our study demonstrates a hitherto unappreciated causal role of Serpins in regulating matrix function and post-infarct cardiac remodelling.
Disproportionately high aortic valve calcium scores in atrial fibrillation: implications for transcatheter aortic valve replacement
Authors: Masson Rajeev , Nkomo Vuyisile T , Holmes David R , Pislaru Sorin V , Arsanjani Reza , Chao Chieh-Ju , Klanderman Molly , Abraham Bishoy , Morsy Mahmoud , Fortuin F David , Sweeney John P , Sell-Dotten Kristen , Alsidawi Said 
Published: April 2024

Abstract

Aims
Doppler mean gradient (MG) can underestimate aortic stenosis (AS) severity in patients with atrial fibrillation (AF) compared with patients with sinus rhythm (SR), potentially delaying intervention in AF. This study compared outcomes in patients with AF and SR following transcatheter aortic valve replacement (TAVR) and investigated delay in TAVR based on computed tomography aortic valve calcium score (AVCS).

Methods and results
Patients who underwent TAVR from 2013 to 2017 for native valve severe AS were identified from an institutional database. Baseline characteristics and overall survival were compared between those with SR and AF. There were 820 patients (mean age 81 years; 41.6% females) included in this study. AF was present in 356 patients. Patients with AF were older (82.2 vs. 80.5, P = 0.003) and had a lower MG compared with patients with SR (42.0 vs. 44.9, P = 0.002) with similar indexed aortic valve area (0.4 vs. 0.4, P = 0.17). Median AVCS was higher in AF (males: AF 2850.0 vs. SR 2561.0, P = 0.044; females: AF 1942.0 vs. SR 1610.5, P = 0.025). Projected AVCS, assuming the same age of diagnosis, was similar between AF and SR. Median survival post-TAVR was worse in AF compared with SR (3.2 vs. 5.4 years, log rank P &lt; 0.001). AF, lower MG, higher right ventricular systolic pressure, dialysis, diabetes, and significant tricuspid regurgitation were associated with higher mortality (P &lt; 0.05 for all).

Conclusion
Older age and higher AVCS in patients with AF compared with those with SR suggest that AS was both underestimated and more advanced at TAVR referral.
Steeper at the top: cognitive ability and earnings in Finland and Norway
Authors: Bratsberg Bernt , Rogeberg Ole , Terviö Marko 
Published: April 2024

Abstract
We document a convex relationship between earnings rank and cognitive ability for men in Finland and Norway using administrative data on over 350,000 men in each country: the top earnings percentile score on average 1 standard deviation higher than median earners, while median earners score about 0.5 standard deviation higher than the bottom percentile of earners. Top earners also have substantially less variation in cognitive test scores. While some high-scoring men are observed to have very low earnings, the lowest cognitive scores are almost absent among the top earners. Overall, the joint distribution of earnings rank and ability is very similar in Finland and Norway. We find that the slope of the ability curve across earnings ranks is steepest in the upper tail, as is the slope of the earnings curve across cognitive ability. The steep slope of the ability curve across the top earnings percentiles differs markedly from the flat or declining slope recently reported for Sweden.
Diabetes and coronary artery disease as risk factors for dementia
Authors: Olesen Kevin K W , Thrane Pernille G , Gyldenkerne Christine , Thomsen Reimar W , Mortensen Janne K , Kristensen Steen D , Maeng Michael 
Published: April 2024

Abstract

Aims
Diabetes is associated with an increased risk of dementia, but it is still debated to which degree this risk depends on the presence of atherosclerotic cardiovascular disease (CVD). In this study, we hypothesize that patients with diabetes and coexisting coronary artery disease (CAD), as a marker of systemic atherosclerotic CVD, have a substantially higher risk of developing dementia.

Methods and results
Patients ≥65 years, who underwent coronary angiography, were stratified by diabetes and CAD. Outcomes were all-cause dementia, Alzheimer’s dementia, and vascular dementia. We estimated adjusted hazard ratios (aHRs) using patients with neither diabetes nor CAD as a reference. A total of 103 859 patients were included. Of these, 23 189 (22%) had neither diabetes nor CAD, 3876 (4%) had diabetes, 61 020 (59%) had CAD, and 15 774 (15%) had diabetes and CAD. During a median follow-up of 6.3 years, 5592 (5.5%) patients were diagnosed with all-cause dementia. Patients with diabetes and CAD had the highest HR of all-cause dementia [aHR 1.37, 95% confidence interval (CI) 1.24–1.51], including Alzheimer’s dementia (aHR 1.41, 95% CI 1.23–1.62) and vascular dementia (aHR 2.03, 95% CI 1.69–2.45). Patients with diabetes alone (aHR 1.14, 95% CI 0.97–1.33) or CAD alone (aHR 1.11, 95% CI 1.03–1.20) had a modestly increased rate of all-cause dementia.

Conclusion
The combination of diabetes and CAD is associated with an increased rate of dementia, in particular vascular dementia, suggesting that the diabetes-related risk of dementia is partly mediated through concomitant atherosclerotic CVD. This underscores the importance of atherosclerotic CVD prevention in diabetic patients to reduce cognitive decline.
Stereotactic arrhythmia radioablation and its implications for modern cardiac electrophysiology: results of an EHRA survey
Authors: Kovacs Boldizsar , Lehmann Helge Immo , Manninger Martin , Saguner Ardan Muammer , Futyma Piotr , Duncker David , Chun Julian 
Published: April 2024

Abstract
Stereotactic arrhythmia radioablation (STAR) is a treatment option for recurrent ventricular tachycardia/fibrillation (VT/VF) in patients with structural heart disease (SHD). The current and future role of STAR as viewed by cardiologists is unknown. The study aimed to assess the current role, barriers to application, and expected future role of STAR. An online survey consisting of 20 questions on baseline demographics, awareness/access, current use, and the future role of STAR was conducted. A total of 129 international participants completed the survey [mean age 43 ± 11 years, 25 (16.4%) female]. Ninety-one (59.9%) participants were electrophysiologists. Nine participants (7%) were unaware of STAR as a therapeutic option. Sixty-four (49.6%) had access to STAR, while 62 (48.1%) had treated/referred a patient for treatment. Common primary indications for STAR were recurrent VT/VF in SHD (45%), recurrent VT/VF without SHD (7.8%), or premature ventricular contraction (3.9%). Reported main advantages of STAR were efficacy in the treatment of arrhythmias not amenable to conventional treatment (49%) and non-invasive treatment approach with overall low expected acute and short-term procedural risk (23%). Most respondents have foreseen a future clinical role of STAR in the treatment of VT/VF with or without underlying SHD (72% and 75%, respectively), although only a minority expected a first-line indication for it (7% and 5%, respectively). Stereotactic arrhythmia radioablation as a novel treatment option of recurrent VT appears to gain acceptance within the cardiology community. Further trials are critical to further define efficacy, patient populations, as well as the appropriate clinical use for the treatment of VT.
Technological Development and Advances for Constructing and Analyzing Plant Pangenomes
Authors: Hu Haifei , Li Risheng , Zhao Junliang , Batley Jacqueline , Edwards David 
Published: April 2024

Abstract
A pangenome captures the genomic diversity for a species, derived from a collection of genetic sequences of diverse populations. Advances in sequencing technologies have given rise to three primary methods for pangenome construction and analysis: de novo assembly and comparison, reference genome-based iterative assembly, and graph-based pangenome construction. Each method presents advantages and challenges in processing varying amounts and structures of DNA sequencing data. With the emergence of high-quality genome assemblies and advanced bioinformatic tools, the graph-based pangenome is emerging as an advanced reference for exploring the biological and functional implications of genetic variations.
Agents of Change: Geriatrics Workforce Programs Addressing Systemic Racism and Health Equity
Authors: Gordon Barbara A , Azer Lilian , Bennett Katherine , Edelman Linda S , Long Monica , Goroncy Anna , Alexander Charles , Lee Jung-Ah , Rosich Rosellen , Severance Jennifer J 
Published: April 2024

Abstract
Many factors affect how individuals and populations age, including race, ethnicity, and diversity, which can contribute to increased disease risk, less access to quality healthcare, and increased morbidity and mortality. Systemic racism—a set of institutional policies and practices within a society or organization that perpetuate racial inequalities and discrimination—contributes to health inequities of vulnerable populations, particularly older adults. The National Association for Geriatrics Education (NAGE) recognizes the need to address and eliminate racial disparities in healthcare access and outcomes for older adults who are marginalized due to the intersection of race and age. In this paper, we discuss an anti-racist framework that can be used to identify where an organization is on a continuum to becoming anti-racist and to address organizational change. Examples of NAGE member Geriatric Workforce Enhancement Programs (GWEPs) and Geriatrics Academic Career Awards (GACAs) activities to become anti-racist are provided to illustrate the framework and to guide other workforce development programs and healthcare institutions as they embark on the continuum to become anti-racist and improve the care and health of vulnerable older adults.
Medicaid spending and utilization of gene and RNA therapies for rare inherited conditions
Authors: Odouard Ilina C , Ballreich Jeromie , Socal Mariana P 
Published: April 2024

Abstract
Gene and RNA therapies are promising treatments for many rare diseases. Pediatric populations that could benefit from these drugs are overrepresented among state Medicaid programs. Using Medicaid State Drug Utilization Data, we examined Medicaid spending and utilization of rare disease gene and RNA therapies. Between 2017 and 2022, the number of available gene and RNA therapies increased from 3 to 13, yearly Medicaid spending increased from $148.3 million to $879.7 million, and the number of yearly treatments (a proxy for number of patients) increased from 327 to 1638. Nearly all spending was attributed to spinal muscular atrophy (SMA) and Duchenne muscular dystrophy drugs. States participating in Medicaid pooled purchasing initiatives had 39% higher treatments per 100 000 enrollees with no differences in spending. Compared to states without a carve-out, states that carved SMA drugs out of managed Medicaid contracts had higher utilization (54%). Spending among carve-out states varied according to managed care enrollment, being higher for those with &lt;80% of enrollees in managed care as compared with those with ≥80% of enrollees in managed care. This suggests that multi-state purchasing initiatives and managed care carve-outs can help increase access to gene and RNA therapies among Medicaid beneficiaries, but it is unclear if these strategies are effective at managing spending.